Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-FR Version v5-FR
Language French French
Date Updated 2021-05-10 2020-12-11
Drug Identification Number 02237815 02237815
Brand name ERWINASE ERWINASE
Common or Proper name Erwinia L-asparaginase Erwinia L-asparaginase
Company Name JAZZ PHARMACEUTICALS FRANCE SAS JAZZ PHARMACEUTICALS FRANCE SAS
Ingredients ASPARAGINASE ASPARAGINASE
Strength(s) 10000UNIT 10000UNIT
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 3 mL vials 3 mL vials
ATC code L01XX L01XX
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2021-04-01 0001-01-01
Actual discontinuation date 2021-04-09
Remaining supply date 2021-02-28 2021-02-28
Discontinuation status Discontinued To be discontinued
Discontinuation decision reversal no no
Information on remaining supply
Company comments Distribution of Erwinase by Jazz Pharmaceuticals will end now that lot 205H121 (“CAMR205”) is exhausted. For all enquiries about future supply beyond Lot 205H121, please contact Sterimax Inc.: Phone: 1-800-881-3550 Fax: 1-877-546-7667 Email: customerservice@sterimaxinc.com Web: www.sterimaxinc.com A separate communication will be issued regarding the supply of Erwinase by Jazz.
Health Canada comments